| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5814792 | Neuropharmacology | 2013 | 10 Pages |
Abstract
⺠Levomilnacipran is the more active enantiomer of the SNRI milnacipran. ⺠It is selective in vitro for NET and SERT versus 23 other targets. ⺠It inhibits NE and 5-HT reuptake in vitro with â¼2-fold greater potency at NET. ⺠The NE/5-HT ratio of reuptake inhibition in vitro is greater than for other SNRIs. ⺠It displays antidepressant/anxiolytic efficacy comparable to that of other SNRIs.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
A.L. Auclair, J.C. Martel, M.B. Assié, L. Bardin, P. Heusler, D. Cussac, M. Marien, A. Newman-Tancredi, J.A. O'Connor, R. Depoortère,